Zomedica Corp. (NYSEAMERICAN:ZOM – Get Rating) was the target of a large decrease in short interest in August. As of August 15th, there was short interest totalling 68,970,000 shares, a decrease of 21.8% from the July 31st total of 88,150,000 shares. Based on an average daily volume of 21,060,000 shares, the short-interest ratio is presently 3.3 days. Currently, 7.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Zomedica

A number of institutional investors and hedge funds have recently bought and sold shares of the company. ExodusPoint Capital Management LP acquired a new position in Zomedica in the 2nd quarter worth about $38,000. Jane Street Group LLC grew its position in shares of Zomedica by 413.9% in the 2nd quarter. Jane Street Group LLC now owns 1,082,261 shares of the company's stock valued at $238,000 after buying an additional 871,646 shares during the last quarter. Millennium Management LLC grew its position in shares of Zomedica by 240.8% in the 2nd quarter. Millennium Management LLC now owns 557,672 shares of the company's stock valued at $123,000 after buying an additional 394,058 shares during the last quarter. West Michigan Advisors LLC grew its position in shares of Zomedica by 50.0% in the 2nd quarter. West Michigan Advisors LLC now owns 126,000 shares of the company's stock valued at $28,000 after buying an additional 42,000 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Zomedica in the 2nd quarter valued at about $552,000. Institutional investors and hedge funds own 12.80% of the company's stock.

Zomedica Stock Down 7.2 %

Shares of ZOM opened at $0.27 on Friday. Zomedica has a 12-month low of $0.18 and a 12-month high of $0.71. The stock has a market capitalization of $260.65 million, a price-to-earnings ratio of -13.30 and a beta of 0.65.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals.

Recommended Stories

• Get a free copy of the StockNews.com research report on Zomedica (ZOM)
• Why This Dip in Advanced Auto Parts May be an Opportunity
• MarketBeat: Week in Review 8/22 – 8/26
• Institutional Buying Put A Bottom In Marvell Technology
• Dell Stock Retreats On Weaker Sales, Falls Into Value Terrirtory
• 3 Reasons Dollar General's Rally Has Legs

Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.